Roche Agreement definition

Roche Agreement means that certain Collaboration and License Agreement, effective as of August 7, 2008, by and among ▇▇▇▇▇▇▇▇-▇▇ ▇▇▇▇▇ Inc., ▇▇▇▇▇ Palo Alto LLC, ▇. ▇▇▇▇▇▇▇▇-▇▇ ▇▇▇▇▇ Ltd. and Target, as amended from time to time.

AI-Powered Contracts

Draft, Review & Redline at the Speed of AI

Roche Agreement means that certain Asset Purchase Agreement, dated as of July 15, 2022, by and among F. Hoffman-La Roche Ltd, Hoffmann La Roche Inc. and Parent.

Roche Agreement means that certain Asset Purchase Agreement, dated as of July 15, 2022, by and among ▇. ▇▇▇▇▇▇▇-▇▇ ▇▇▇▇▇ Ltd, ▇▇▇▇▇▇▇▇ ▇▇ ▇▇▇▇▇ Inc. and Parent.

Examples of Roche Agreement in a sentence

Without limiting the foregoing, Parent and its Affiliates shall pursue their rights under the Roche Agreement in good faith, and not take any action (or fail to take any action) with the intention of avoiding, reducing or materially delaying any payment to the Holders hereunder.
Upon termination of the Roche Agreement (or expiration of the license term of the End User Agreement), Customer must immediately cease use of the Tableau Software and remove the Tableau Software from its systems.
Notwithstanding anything contained herein to the contrary, Buyer shall have sole discretion and decision making authority, which shall be exercised in good faith and with commercial reasonableness, with respect to the Roche Agreement; provided, that in no event shall declining to effect a Roche Purchase Payment Event or any other decision to retain existing rights under the Roche Agreement be deemed not to satisfy the “in good faith and with commercial reasonableness” standard.
Borrower shall not, without the consent of Agent, terminate, or amend in a manner materially adverse to the Lenders, the Roche Agreement.
This clause 33 is in addition to, and does not relieve, remove or replace, a party's obligations under the Data Protection Legislation.

More Definitions of Roche Agreement

Roche Agreement means that certain Research, Development and Commercialization Agreement, dated as of December 18, 2008, by and between ▇▇▇▇▇▇▇▇ (as successor in interest to VIA Pharmaceuticals, Inc.), ▇▇▇▇▇▇▇-▇▇ ▇▇▇▇▇ Inc. and ▇. ▇▇▇▇▇▇▇▇-▇▇ ▇▇▇▇▇ Ltd, as amended, restated, amended and restated, supplemented or otherwise modified from time to time.

Roche Agreement means the Amended and Restated Co-Promotion Agreement between ▇▇▇▇▇▇▇▇-▇▇ ▇▇▇▇▇ Inc. and ▇. ▇▇▇▇▇▇▇▇-▇▇ ▇▇▇▇▇ Ltd. (collectively, “Roche”) and GSK dated December 6, 2001, as amended from time to time, pursuant to which GSK and Roche are commercializing Bonviva™ in certain countries of the world and Boniva™ in the United States of America (such product, “Bonviva™” and such program, the “Bonviva™ program”).

Roche Agreement has the meaning set forth in Section 1.18.

Roche Agreement means that certain Research, Development and Commercialization Agreement, dated as of December 18, 2008, by and between ▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇-▇▇ ▇▇▇▇▇ Inc. and ▇. ▇▇▇▇▇▇▇▇-▇▇ ▇▇▇▇▇ Ltd, as in effect on the Closing Date and as amended form time to time in accordance with the terms of this Agreement. “Royalty Monetization Transaction” means any monetization or financing transaction involving (a) the sale, transfer, option or collateralization of (i) any monetary payments (contingent or otherwise) payable to Borrower or its Subsidiaries by a counterparty under a Product Agreement, or (ii) any revenues generated through the commercial sale of the Product to third parties, in each case whether in whole or in part or (b) the provision of financing for the development, manufacture and/or Commercialization of any Product in exchange for the future payment of royalties, milestones and other amounts (whether or not contingent), including but not limited to sales of royalty streams, royalty bonds and other royalty financings, synthetic royalty, development financing, and revenue interest transactions (including but not limited to clinical trial funding arrangements), and hybrid monetization transactions. “S&P” means Standard & Poor’s Ratings Group, a division of The McGraw Hill Corporation. “Sanctioned Entity” means (a) a country or territory or a government of a country or territory, (b) an agency of the government of a country or territory, (c) an organization directly or indirectly controlled by the government of a country or territory, or (d) a Person ordinarily resident in a country or territory, in each case of clauses (a) through (d) that is a Sanctioned Jurisdiction. “Sanctioned Jurisdiction” means, at any time, each country or territory that is or has since April 24, 2019, been subject to a comprehensive OFAC Sanctions Program. As of the Closing Date, the

Roche Agreement means that certain Asset Purchase Agreement, dated as of July 15, 2022, by and among ▇. ▇▇▇▇▇▇▇-▇▇ ▇▇▇▇▇ Ltd, ▇▇▇▇▇▇▇▇ ▇▇ ▇▇▇▇▇ Inc. and Parent. “Roche Payment Amount” means the thirty million dollar ($30,000,000) milestone payment to be made by Roche to Parent upon the initiation of a phase III clinical study in diabetic macular disorder with the compound known as “EBI-031” during the CVR Term, as set forth in Section 11.1 of the Roche Agreement. “Third Party” means any Person other than Parent, Rights Agent or their respective Affiliates. “Total Payment Amount” means, as of any applicable time of determination, any Asset Disposition Proceeds plus any Roche Payment Amounts.

Roche Agreement means that certain Collaborative Research, Development and Commercialization Agreement between the Company and Roche dated September 19, 2002, as amended.

Roche Agreement means an agreement entered into on July 18, 2003 as amended on February 4, 2005, December 22, 2005, March 13, 2007 and August 17, 2007 between Aspreva Pharmaceuticals S.A. and Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd. (collectively “Roche”) for the development and commercialization of Specified Pharmaceutical Product;